Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments (the eServices portal) close on Thursday 26 January at 4:30pm because of system upgrades. We expect to open them again on Friday 27 January at 8am the latest.

The innovation environment Nollvision Cancer

The innovation environment Nollvision Cancer is to be a national contact point for system innovation that contributes to reducing the incidence of cancer and transforming cancer from a fatal to a curable or chronic disease in Sweden and globally.

This web page has been machine translated. If there are any uncertainties, please refer to the Swedish text.

- Cancer research and innovation must be prioritized and better integrated into healthcare. Stronger cooperation is needed. Many actors have testified that they lack platforms and forums to exchange knowledge and experiences and to be able to test and implement new solutions, says Hans Hägglund, national cancer coordinator at Sveriges Kommuner and Regions, SKR, and project manager for Nollvision cancer.

The innovation environment must break today's lock-ins and create the conditions for cross-disciplinary and cross-sector collaborations. It should be easier for patients, healthcare, academia, industry and politics to come together and work methodically together in research and innovation in order to quickly introduce new working methods, techniques and treatments that benefit patients and society.

Five target areas

To work towards the vision, the initiators have identified a number of measurable sub-goals within five overlapping target areas in need of renewal:

Prevention

  • Early detection and diagnosis
  • Treatment and quality of life
  • Research, clinical trials and registries
  • Organization, economy and ethics

During the first two years, the innovation environment focuses on lung cancer, which is the most common cause of cancer-related death in the world. The working model that is developed must then be able to be used for other diagnoses.

Well-established innovation environment

Nollvision cancer will contribute in the long term to realizing Agenda 2030 by improving cancer care and making it more equal and strengthening Sweden's international competitiveness in life science. The innovation environment also works towards several objective in the national cancer strategy, the national life science strategy and the government's and the Regional Cancer Center's, RCC's, direction for Swedish cancer care.

The innovation environment is well anchored in the Government Office through the agreement between the state and SKR that was signed in December 2019, "Equal and efficient cancer care with shorter waiting times in 2020". It is also anchored in RCC's direction for Swedish cancer care in 2020–2022, where an objective for the target area Research and innovation is that there should be a platform for system innovation with the aim of transforming cancer from a fatal to a curable or chronic disease in Sweden and globally.

Start-up

During the initial phase up to and including 2021, the goal is to start efforts within the five target areas, to gather more actors who stand behind the vision and want to contribute to the work, and to make the innovation environment known nationally and internationally, including by participating in the Swedish stand at the world exhibition Expo 2020 in Dubai.

- Our vision is ambitious, and not something that a single actor can achieve. We hope that Sweden can lead the way and become a role model for many countries and that our work will ultimately benefit patients worldwide, says Hans Hägglund.

Initiator

National cancer coordinator at Sveriges Kommuner and Regions and chairman of the Regional Cancer Center in collaboration with:

AstraZeneca, Cancer Foundation, Elekta, Stockholm School of Economics, Kliniskt Centrum for Health Promotion Care at Lund University, Leading Health Care, LIF – The research pharmaceutical companies, Lung Cancer Association, SLUSG Swedish Lung Cancer Study Group, STUNS/Uppsala BIO, Swedish Medtech and Swelife.

Learn more at nollvisioncancer.se

Report from the area

In this film, representatives of the innovation environment Nollvision cancer talk about how they worked vision-driven, their lessons learned and results from the first two years.

You have chosen to disallow certain cookies and funtions on our website, such as videoclips from YouTube. You can change your privacy settings at any time to allow these functions and get a better experience.

Change your privacy settings

Watch video on external page

Questions?

If you want to know more and get involved in Nollvision cancer, contact one of us.

Ebba Hult

Center for AI, Innovation and the future of work, House of innovation, Stockholm School of Economics

+46 72 711 44 91

Caroline Ekstrand

Programme Manager

+46 8 473 30 27

Last updated 6 October 2022

Page statistics